Seattle Genetics, Inc. (SGEN)
(Delayed Data from NSDQ)
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[SGEN]
Reports for Purchase
Showing records 1 - 20 ( 230 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SGEN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Dynamics Catalysts Across the Urothelial Cancer Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Bladder Cancer KOL Dinner Highlights-Innovations, Inconsistencies and Experimentation Shape the UC Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Poised For Growth in All the Right Oncologic Directions; Reit. Buy and $180 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R